* State budget-balancing measure leads to shift in PERA contributions
* Branding initiative endorsed, adopted by Board of Regents
* UPDATE: Flex bill clears first hurdle at Capitol
* Guiding principles, presidential search go back to governance groups
* Federal stimulus has brought $151 million to CU for research
* Five questions for Kerry Paterson
* Did you know...
* People
* Letters to the Editor
  Stimulus grant brings $15 million to biotechnology building
  Breast cancer risk factors differ among races
  Successful blog creator shares experience with students
  Some pediatric brain tumors might be worsened by immune gene expression
   Newsletter Archive
Download Newsleter in PDF
Share your thoughts
Share your opinions

Send your thoughts and suggestions for the Newsletter

News from the CU system - Anschutz Medical Campus

Some pediatric brain tumors might be worsened by immune gene expression

Nicholas Foreman, M.D.
More than half of children diagnosed with ependymoma brain tumors will have them recur after standard treatment — surgery and radiation — and lead to death. University of Colorado Cancer Center researcher Nicholas Foreman, M.D., calls it "one of the most significant problems in pediatric neuro-oncology."

Foreman, director of pediatric neuro-oncology at The Children's Hospital and professor of pediatrics at the University of Colorado School of Medicine, and colleagues last year identified the reason why half of the tumors recur. He has just been awarded a $1.2 million, four-year grant from the National Cancer Institute to dig deeper into the discovery that expression of certain genes linked with immune function predicted good outcomes.

About one in 11 pediatric brain tumors are ependymomas, with about 200 new diagnoses of the disease in the United States each year. Brain tumors are the most common cause of childhood cancer death, according to the National Cancer Institute.

"As we looked closely at the tumor cells, we realized this immune expression wasn't a function of the tumor, but of the immune cells which, in some cases, were in large quantities in the tumor," Foreman said. "It turned out to be the first demonstration in any brain tumor that the immune status of the individual at diagnosis is directly related to his or her chance of being cured."

The researchers also found that certain aspects of the immune function could be blocking treatment's effectiveness, which flies against common belief that all immune reactions to a tumor are positive. Activation of macrophages, a type of immune cell, could trigger release of antibodies that work counter to treatment. These antibodies might serve both as a marker for poor outcome and a treatment target, Foreman says.

"The immune system is more complex than people had realized," he said. "Using this new grant, we hope to identify which parts of immune function is good for killing these brain tumors and which parts help keep them alive or help them grow."

Foreman's work is based on a human model of the immune system and outcomes. Most other experiments have been done in animal models, which might work differently than human systems.

In the long run, Foreman hopes the studies lead to a blood test that will tell doctors at diagnosis whether a child will have a good or poor outcome with standard treatment, and a method for manipulating patients' immune system during standard treatment to make it more effective.

The discovery was published in the Nov. 16, 2009, issue of the Journal of Immunology by Foreman and colleagues from the School of Medicine and Children's Oncology Group, a national research group. The experiments were initially done using tumor tissue samples Foreman began collecting when he arrived in Denver in 1995. The new studies will be done on tissue collected by centers across the country.

Bookmark - Print - Share

Previous Anschutz Medical Campus Stories

School of Medicine, partners will work to prevent mistreatment of children

University of Colorado Hospital provides funding for new crisis services system

University of Colorado Cancer Center researchers receive $3.5 million grant

Hospital receives distinguished designation for excellence in nursing

Regional stem-cell center launched by School of Medicine

School of Medicine program receives oral health grant

UC Denver one of top places for postdocs to work

University of Colorado Hospital internal medicine, specialty clinic relocating

New type of complex genetic variation discovered

UC Denver announces state's first bioengineering department

School of Dental Medicine gives kids a smile

Emergency medicine physicians take part in suicide research trial

Researchers receive grant to study impact of law on public health practice

Assembling planet's Tree of Life less daunting thanks to researchers

State-of-the-art imaging offers enhanced treatment for arrhythmia

Rural medicine, Down syndrome programs receive federal support

Study highlights lack of knowledge regarding hospital medications

School of Pharmacy researcher receives funding from Michael J. Fox Foundation

New UC Denver program puts high school grads on pathway to med school

Award of $577,000 will aid study of tuberculosis treatment

Depression Center works to establish national network

School of Medicine to take part in nationwide study of blood pressure

College of Nursing expands offerings in Western Regional Graduate Program

Study: Tanning associated with moles in very light-skinned children

When the laboratory meets the studio

When the laboratory meets the studio

Cancer Center scientists win $870,000 ARRA Challenge Grant

Cancer Center scientists win $870,000 ARRA Challenge Grant

University of Colorado Cancer Center wins National Cancer Institute grant

Ground broken on planned VA medical center

SOM, state labor department to manage training facility

Pulmonary hypertension drug helps former smokers

Breast cancer researcher receives gift from Avon